| Literature DB >> 29705120 |
Kamile Leonardi Dutra1, Lunardo Longo2, Liliane Janete Grando3, Elena Riet Correa Rivero3.
Abstract
INTRODUCTION: Reactive hyperplastic lesions develop in response to a chronic injury simulating an exuberant tissue repair response. They represent some of the most common oral lesions including inflammatory fibrous hyperplasia, oral pyogenic granuloma, giant cell fibroma, peripheral ossifying fibroma, and peripheral giant cell lesions.Entities:
Keywords: Cavidade oral; Giant cell granuloma; Granuloma de células gigantes; Granuloma piogênico; Hiperplasia; Hyperplasia; Lesões hiperplásicas reativas; Oral cavity; Pyogenic granuloma; Reactive hyperplastic lesions
Mesh:
Year: 2018 PMID: 29705120 PMCID: PMC9443062 DOI: 10.1016/j.bjorl.2018.03.006
Source DB: PubMed Journal: Braz J Otorhinolaryngol ISSN: 1808-8686
Figure 1General incidence of lesions recorded as it relates to the histologic type.
Cases diagnosed distributed by gender.
| Diagnoses | Male | Female | ||
|---|---|---|---|---|
| % | % | |||
| Inflammatory fibrous hyperplasia | 91 | 24 | 294 | 76 |
| Oral pyogenic granuloma | 16 | 26 | 46 | 74 |
| Giant cell fibroma | 15 | 38 | 24 | 62 |
| Peripheral ossifying fibroma | 04 | 14 | 24 | 86 |
| Peripheral giant cell lesions | 11 | 61 | 07 | 39 |
Distribution according to the patients’ age.
| Diagnoses | Age group (%) | ||||||
|---|---|---|---|---|---|---|---|
| 0–19 | 20–29 | 30–39 | 40–49 | 50–59 | 60–69 | <70 | |
| Inflammatory fibrous hyperplasia | 03 | 02 | 10 | 22 | 32 | 22 | 10 |
| Oral pyogenic granuloma | 22 | 18 | 17 | 13 | 22 | 3 | 5 |
| Giant cell fibroma | 22 | 14 | 08 | 33 | 24 | 3 | – |
| Peripheral ossifying fibroma | 11 | 25 | 22 | 14 | 14 | 14 | – |
| Peripheral giant cell lesions | 45 | 11 | 5.5 | 11 | 11 | 11 | 5.5 |
Distribution according to the predominant location of the lesion.
| Diagnoses | Gingival/alveolar ridge | Tongue | Jugal mucosa | Palate | Lip | Other | |
|---|---|---|---|---|---|---|---|
| Inflammatory fibrous hyperplasia | 85 | 55 | 80 | 32 | 67 | 66 | 385 |
| Oral pyogenic granuloma | 34 | 13 | 01 | 02 | 11 | 02 | 63 |
| Giant cell fibroma | 10 | 19 | 06 | 02 | 01 | – | 38 |
| Peripheral ossifying fibroma | 28 | – | – | – | – | – | 28 |
| Peripheral giant cell lesions | 18 | – | – | – | – | – | 18 |
Figure 2(A) Inflammatory fibrous hyperplasia; (B) ill-fitting denture over the inflammatory fibrous hyperplasia; (C) oral pyogenic granuloma in the alveolar ridge; (D) oral pyogenic granuloma in the lower lip; (E) peripheral ossifying fibroma; (F) periapical radiography of the peripheral ossifying fibroma; (G) peripheral giant cell lesions; (H) giant cell fibroma.
Distribution according to the etiological factor.
| Diagnoses | Ill-fitting denture | Chronic injury | Remaining root | Dental extraction | Bacterial plaque | Implants | Orthodontic brackets | Others | |
|---|---|---|---|---|---|---|---|---|---|
| IFH | 169 | 68 | – | – | – | – | 03 | 04 | 244 |
| OPG | 07 | 11 | – | 01 | 04 | 02 | – | – | 25 |
| GCF | 10 | 04 | – | – | – | – | – | – | 14 |
| POF | 01 | 01 | 01 | 01 | 03 | – | – | – | 07 |
| PGCL | 02 | 01 | 01 | 01 | – | – | – | – | 05 |
| Total | 189 | 85 | 02 | 03 | 07 | 02 | 03 | 04 | 295 |
IFH, inflammatory fibrous hyperplasia; OPG, oral pyogenic granuloma; GCF, giant cell fibroma; POF, peripheral ossifying fibroma; PGCL, peripheral giant cell lesions.
Figure 3Distribution according to concordance among clinical and histopathological diagnoses.
Figure 4Hematoxylin and eosin staining. (A) Inflammatory fibrous hyperplasia (40×); (B) high magnification of the same case showing thick collagen fibers (100×); (C) oral pyogenic granuloma (100×); (D) high magnification of the same case showing greater number of endothelial cells and newly formed blood vessels (400×); (E) giant cell fibroma, with thin and long epithelial projections (100×); (F) high magnification of the same case showing the presence of stellate-shaped (arrow) and multinucleated (arrowhead) fibroblasts (400×); (G) peripheral ossifying fibroma, with mineralized product in the connective tissue (40×); (H) high magnification of the same case demonstrating irregular bone trabeculae formed (100×); (I) peripheral giant cell lesions (100×); (J) high magnification of the same case with large number of multinucleated giant cells associated with hemorrhagic areas (400×).
Long-term results of reactive hyperplasic lesions recorded from the literature. Data are percentage (%) unless otherwise stated.
| Author, year, country | Total sample | RHL | Histopathological diagnosis | Gender | Age group (y) | Predominant location | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Alveolar ridge | Tongue | Jugal mucosa | Palate | Lip | Other | ||||||
| Zarei et al., 2007 – Iran | 172 | 100.0 | IFH 19.1 | 26.0 | 14–76 (39.0) | – | – | – | – | – | – |
| OPG 26.1 | 31.0 | 7–64 (27.0) | – | – | – | – | – | – | |||
| POF 10.4 | 10.0 | 10–49 (24.0) | – | – | – | – | – | – | |||
| PGCL 18.6 | 13.0 | 5–72 (13.0) | – | – | – | – | – | – | |||
| Amirchaghmaghi et al., 2011 – Iran | 123 | 100.0 | IFH 40.6 | 36.0 | (39.0) | 20.0 | 28.0 | 30.0 | 8.0 | 10.0 | 4.0 |
| OPG 25.2 | 19.0 | 64.5 | 3.2 | 9.6 | 9.6 | 6.4 | 6.4 | ||||
| POF 5.6 | 6.0 | 71.4 | 0.0 | 14.2 | 14.2 | 0.0 | 0.0 | ||||
| PGCL 27.6 | 19.0 | 85.2 | 0.0 | 2.9 | 2.9 | 0.0 | 8.8 | ||||
| Maturana-Ramírez et al., 2011 – Chile | 6369 | 18.0 | IFH 71.1 | 70.7 | 0–19 (31.1) | 18.5 | 19.4 | 20.6 | 0.0 | 16.6 | 24.7 |
| OPG 21.1 | 79.3 | 20–29 (8.5) | |||||||||
| POF 2.9 | 57.1 | 30–39 (12.7) | |||||||||
| PGCL 5.0 | 48.4 | 40–49 (19.5) | |||||||||
| <50 (47.3) | |||||||||||
| Kashyap et al., 2012 – India | 240 | 41.6 | IFH 35.0 | 31.0 | 16–59 | 34.2 | 14.2 | 51.4 | 0.0 | 0.0 | 0.0 |
| OPG 42.0 | U | (34.0) | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |||
| POF 18.0 | 38.8 | (39.0) | – | – | – | – | – | – | |||
| PGCL 10.0 | 50.0 | (33.0) | – | – | – | – | – | – | |||
| Reddy et al., 2012 India | 1634 | 12.7 | IFH 57.4 | 36.5 | (74.1) | 74.1 | 4.1 | 12.5 | 5.0 | 4.1 | 0 |
| OPG 18.7 | 74.3 | (28.0) | 89.7 | 0.0 | 5.1 | 0.0 | 5.1 | 0.0 | |||
| POF 17.7 | 72.9 | (32.4) | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |||
| PGCL 6.22 | 53.8 | (29.1) | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |||
| Palmeira et al., 2013 – Brazil | 938 | 35.0 | IFH 82.6 | 73.0 | 40–59 (44.0) | 40.9 | 14.0 | 16.1 | 12.2 | 11.0 | 5.8 |
| OPG 11.1 | |||||||||||
| PGCL 6.1 | |||||||||||
| Vidyanath et al., 2015 – India | 2753 | 10.7 | IFH 51.9 | 71.4 | – | 64.8 | 9.5 | 18.6 | 3.1 | 3.4 | 0.6 |
| OPG 26.3 | |||||||||||
| POF 9.8 | |||||||||||
| PGCL 3.0 | |||||||||||
U, unclear information reported; y, years; –, not reported information; IFH, inflammatory fibrous hyperplasia; OPG, oral pyogenic granuloma; GCF, giant cell fibroma; POF, peripheral ossifying fibroma; PGCL, peripheral giant cell lesions.
These studies reported only RHL, thus the total sample is equal to the RHL sample.